Status:
TERMINATED
Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel
Lead Sponsor:
Johns Hopkins University
Conditions:
Urologic Diseases
Hypospadias
Eligibility:
All Genders
6+ years
Phase:
PHASE3
Brief Summary
This study aims to evaluate the utility of long-acting liposomal bupivacaine (Exparel®) in improving pain scores and reducing narcotic pain requirements in pediatric patients following minor urologic ...
Eligibility Criteria
Inclusion
- Pediatric patients 6 years and older undergoing minor pediatric urologic surgery
- Patients who are otherwise eligible to receive routine care following minor urologic surgery
Exclusion
- Contraindication to receiving local anesthetics (i.e. pre-existing cardiac, renal, hepatic dysfunction)
- Pediatric patients younger than 6 years of age
- Pediatric patients with a history of pain syndromes or are unable to tolerate opiate medication
- Unwilling to participate in 48 hours and 10-14 day follow-up phone calls
Key Trial Info
Start Date :
October 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 26 2023
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT04826484
Start Date
October 1 2021
End Date
April 26 2023
Last Update
December 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287